Eric Schadt Purchases 100,000 Shares of Sema4 Holdings Corp. (NASDAQ:SMFR) Stock

Sema4 Holdings Corp. (NASDAQ:SMFRGet Rating) insider Eric Schadt bought 100,000 shares of the stock in a transaction on Friday, May 20th. The stock was acquired at an average price of $1.92 per share, with a total value of $192,000.00. Following the completion of the acquisition, the insider now owns 243,380 shares of the company’s stock, valued at approximately $467,289.60. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ:SMFR traded down $0.14 during mid-day trading on Tuesday, hitting $1.70. 1,267,695 shares of the company traded hands, compared to its average volume of 1,735,094. The company has a quick ratio of 3.72, a current ratio of 4.08 and a debt-to-equity ratio of 0.03. Sema4 Holdings Corp. has a 12-month low of $1.49 and a 12-month high of $15.21. The stock has a 50-day moving average price of $2.49 and a two-hundred day moving average price of $3.83.

Sema4 (NASDAQ:SMFRGet Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05. The company had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $50.90 million. On average, sell-side analysts forecast that Sema4 Holdings Corp. will post -0.76 earnings per share for the current fiscal year.

SMFR has been the subject of a number of research analyst reports. Cowen lowered their target price on Sema4 from $13.00 to $5.00 in a report on Monday, May 16th. Zacks Investment Research cut Sema4 from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Compass Point reduced their price objective on Sema4 to $5.00 and set a “na” rating for the company in a research note on Monday, May 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $7.54.

A number of institutional investors have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C lifted its holdings in Sema4 by 0.9% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 13,966,824 shares of the company’s stock worth $62,292,000 after acquiring an additional 118,336 shares during the period. SB Management Ltd bought a new stake in Sema4 during the third quarter worth $68,473,000. Vanguard Group Inc. lifted its holdings in Sema4 by 67.6% during the first quarter. Vanguard Group Inc. now owns 5,518,333 shares of the company’s stock worth $16,941,000 after acquiring an additional 2,226,502 shares during the period. Casdin Capital LLC bought a new stake in Sema4 during the third quarter worth $37,950,000. Finally, Third Point LLC lifted its holdings in Sema4 by 53.7% during the fourth quarter. Third Point LLC now owns 4,295,000 shares of the company’s stock worth $19,156,000 after acquiring an additional 1,500,000 shares during the period.

About Sema4 (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Featured Articles

Insider Buying and Selling by Quarter for Sema4 (NASDAQ:SMFR)

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.